Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-08

Study Completion Date

2019-12-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the pharmacokinetic pattern of amino acid absorption after a two-week pattern of milk protein supplementation with and without the addition of Bacillus coagulans GBI-30, 6086.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Changes in Amino Acid Absorption After Adding a Probiotic to an Acute Protein Feeding

NCT06701604

Amino Acid Absorption Probiotic

NOT_YET_RECRUITING NA

Changes in Plasma Amino Acid Appearance After Adding Bacillus Coagulans GBI-30, 6086 to Milk Protein Concentrate

NCT05313178

Protein Malabsorption

COMPLETED NA

Probiotic-Muscle Study

NCT04297111

Old Age; Debility Muscle Weakness Protein Deregulation +1 more

COMPLETED NA

Protein-bound Versus Free Amino Acid Nutrition During INtestinal Malabsorption in Critical Illness

NCT04791774

Intestinal Malabsorption Critical Illness Protein Malnutrition

COMPLETED NA

Amino Acids in the Blood After Eating Yoghurt and Milk Proteins

NCT07243730

Bioavailability of Amino Acids

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will be conducted using a randomized, double-blind, crossover study design. 30 healthy men and women between the ages of 18 - 55 years of age will be recruited to participate in this study. Prior to beginning the study, all participants will sign an IRB-approved informed consent document and complete a healthy history questionnaire to determine study eligibility. Two supplementation protocols that each span two weeks will be completed and separated with a washout period of three weeks. For each study visit, all participants will report to the laboratory between 0600 - 1000 hours after observing an 8 - 10-hour fast. For two weeks prior to each study visit, participants will be assigned in a randomized, double-blind, crossover fashion to ingest a single daily 25-gram dose of a milk protein concentrate or a similar dose of milk protein concentrate plus bacillus coagulans GBI-30, 6086. Upon arrival for each study visit, participants will have their resting heart rate, blood pressure, body mass, height, and body composition measured using bioelectrical impedance analysis (BIA). Upon ingestion of their final assigned supplementation dose, standard multiple sample phlebotomy approaches will used to collect approximately 10mL of venous blood from a forearm vein before (0 min), 30, 60, 90, 120, 180, and 240 minutes after ingestion of their final assigned supplementation dose for that period in the study protocol. Participants will be provided 200 mL of cold water to ingest after each blood collection. Upon processing, all blood samples will be stored at -80 C. All samples will o be discarded according to Institutional Review Board-stipulated guidelines. Study participants will be provided an additional two-week supply of the alternative treatment to begin after observing a three-week washout. After two weeks of supplementation, study participants will return to the laboratory for their remaining testing visit. All subsequent study visits will be completed in a randomized fashion to minimize any order effects from testing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amino Acid Absorption

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

DOUBLE

Participants Investigators

Protein and probiotics were delivered separately. Upon arrival a faculty member (who was not an investigator) blinded both the protein and probiotic samples and kept the code sealed in an envelope until all statistical analysis was complete. Once all data collection, data entry, and statistical analysis was completely finished, the study code was broken.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Milk Protein + Probiotic

25 gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086

Group Type EXPERIMENTAL

Milk protein + GBI-30

Intervention Type DIETARY_SUPPLEMENT

Both conditions matched flavor, color, and serving size

Milk Protein

25 gram dose of milk protein concentrate

Group Type ACTIVE_COMPARATOR

Milk protein

Intervention Type DIETARY_SUPPLEMENT

Both conditions matched flavor, color, and serving size

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Milk protein + GBI-30

Both conditions matched flavor, color, and serving size

Intervention Type DIETARY_SUPPLEMENT

Milk protein

Both conditions matched flavor, color, and serving size

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All participants will be between the ages of 18-55 years.
* Participants will be healthy and free of disease as determined by evaluation of a medical history.
* Completing at least 30 minutes of moderate exercise three days per week

Exclusion Criteria

* Those individuals less than 18 and greater than 55 years of age will be excluded.
* Any individual who is currently being treated for or diagnosed with a cardiac disorder or disease
* Any individual who is currently being treated for or diagnosed with a respiratory disorder or disease
* Any individual who is currently being treated for or diagnosed with a circulatory disorder or disease
* Any individual who is currently being treated for or diagnosed with a musculoskeletal disorder or disease
* Any individual who is currently being treated for or diagnosed with a metabolic disorder or disease
* Any individual who is currently being treated for or diagnosed with obesity (defined as body mass index \> 30 kg/m and body fat greater than 30%)
* Any individual who is currently being treated for or diagnosed with an immune or autoimmune disorder or disease
* Any individual who is currently being treated for or diagnosed with a psychiatric disorder or disease
* Any individual who is currently being treated for or diagnosed with a hematological disorder or disease
* Any individual who is currently being treated for or diagnosed with a neurological disorder or disease
* Any individual who is currently being treated for or diagnosed with an endocrinological disorder or disease
* Participants who are determined to not be weight stable defined as measured body mass deviating by 2% or more.
* Participants who do not or are not willing to abstain from alcohol, nicotine, and caffeine for 12 hours prior to each visit will be excluded
* Participants who do not or are not willing to abstain from exercise for 12 hours prior to each visit will be excluded.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes